Article Text

Download PDFPDF

4CPS-178 Durability of treatment and reasons for discontinuation of dimethyl fumarate and teriflunomide in patients with multiple sclerosis
  1. B Garcia Javier1,
  2. A Sánchez1,
  3. A Cano2,
  4. M Bitlloch1,
  5. A Corderi1,
  6. M Sancho1,
  7. L Pérez1,
  8. L López1,
  9. R Merino1,
  10. L Campins1
  1. 1Hospital De Mataró, Pharmacy, Mataró, Spain
  2. 2Hospital De Mataró, Neurology, Mataró, Spain


Background and Importance Dimethyl fumarate (DMF) and teriflunomide (TRF) are oral immunomodulatory drugs used in the treatment of relapsing-remitting multiple sclerosis (RRMS) since 2015.

Aim and Objectives To determine the durability of treatment and to analyse the reasons for discontinuation of DMF and TRF in patients with RRMS.

Material and Methods An observational, retrospective and longitudinal study was conducted. All patients with RRMS treated with DMF and TRF from 2015 to September 2022 were included. The variables analysed were sex, age, initial Expanded Disability Status Scale (EDSS) score, previous treatments, treatment starting date and treatment discontinuation date, reasons for discontinuation and adverse reactions that led to treatment discontinuation. Treatment discontinuation free-survival was calculated using a Kaplan-Meier method and survival curves were compared using log-rank test. Statistical significance was set at p < 0.05.

Results 97 patients were included, 66 treated with DMF (median age 43.6 ± 10.5 years, women 57.6%, 2 ± 1.4 EDSS at baseline) and 31 treated with TRF (median age 49.1 ± 8.9 years, women 58.1%, 1.5 ± 1.6 EDSS at baseline). Treatment was discontinued by 41 patients (62.1%) in the DMF group and 22 patients (70.9%) in the TRF group (p = 0.27). Median of treatment discontinuation free-survival in DMF group was 24.2 months (IC95% 0 – 62.2) and 17.5 months (IC95% 0 – 44.1) in TRF group (p = 0.29). Reasons for treatment discontinuation were due to disease progression (43.9% in DMF vs 63.9% in TRF, p = 0.13), adverse reaction (53.7% in DMF group vs 31.8% in TRF group, p = 0.09), loss to follow-up (2.4% in DMF group) and patient‘s decision (4.5% in TRF group). Adverse reactions leading to discontinuation of treatment in the DMF group were limphopenia (36.6%), gastrointestinal intolerance (9.7%), diarrhoea (2.4%), generalised severe pruritus (2.4%) and hypotension (2.4%). Adverse reactions that led to treatment discontinuation in the TRF group were diarrhoea (13.6%), elevated transaminases (9.1%), allergy (4.5%) and alopecia (4.5%).

Conclusion and Relevance In this study, no statistically significant differences were found in the durability of DMF and TRF treatments in patients with RRMS.

Patients with DMF tend to discontinue more due to adverse reactions and patients with TRF more due to disease progression.

References and/or Acknowledgements No conflict of interest.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.